Taiwan · Delayed Price · Currency is TWD Applied BioCode Statistics
Total Valuation
Applied BioCode has a market cap or net worth of TWD 2.40 billion. The enterprise value is 1.89 billion.
| Market Cap | 2.40B |
| Enterprise Value | 1.89B |
Important Dates
The next estimated earnings date is Monday, May 11, 2026.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Applied BioCode has 102.81 million shares outstanding. The number of shares has increased by 13.29% in one year.
| Current Share Class | 102.81M |
| Shares Outstanding | 102.81M |
| Shares Change (YoY) | +13.29% |
| Shares Change (QoQ) | -0.57% |
| Owned by Insiders (%) | 10.29% |
| Owned by Institutions (%) | 6.92% |
| Float | 75.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.05 |
| PB Ratio | 3.73 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.40 |
| EV / Sales | 3.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.03 |
Financial Position
The company has a current ratio of 6.78, with a Debt / Equity ratio of 0.09.
| Current Ratio | 6.78 |
| Quick Ratio | 5.46 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -140.73 |
Financial Efficiency
Return on equity (ROE) is -26.44% and return on invested capital (ROIC) is -17.44%.
| Return on Equity (ROE) | -26.44% |
| Return on Assets (ROA) | -12.53% |
| Return on Invested Capital (ROIC) | -17.44% |
| Return on Capital Employed (ROCE) | -25.20% |
| Weighted Average Cost of Capital (WACC) | 8.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, Applied BioCode has paid 79,000 in taxes.
| Income Tax | 79,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.78% in the last 52 weeks. The beta is 0.79, so Applied BioCode's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +3.78% |
| 50-Day Moving Average | 24.23 |
| 200-Day Moving Average | 21.95 |
| Relative Strength Index (RSI) | 42.52 |
| Average Volume (20 Days) | 202,705 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Applied BioCode had revenue of TWD 475.20 million and -201.20 million in losses. Loss per share was -1.96.
| Revenue | 475.20M |
| Gross Profit | 260.89M |
| Operating Income | -223.33M |
| Pretax Income | -201.12M |
| Net Income | -201.20M |
| EBITDA | -166.96M |
| EBIT | -223.33M |
| Loss Per Share | -1.96 |
Balance Sheet
The company has 569.59 million in cash and 59.56 million in debt, with a net cash position of 510.03 million or 4.96 per share.
| Cash & Cash Equivalents | 569.59M |
| Total Debt | 59.56M |
| Net Cash | 510.03M |
| Net Cash Per Share | 4.96 |
| Equity (Book Value) | 643.22M |
| Book Value Per Share | 6.26 |
| Working Capital | 731.92M |
Cash Flow
In the last 12 months, operating cash flow was -226.64 million and capital expenditures -8.82 million, giving a free cash flow of -235.46 million.
| Operating Cash Flow | -226.64M |
| Capital Expenditures | -8.82M |
| Depreciation & Amortization | 56.38M |
| Net Borrowing | -19.01M |
| Free Cash Flow | -235.46M |
| FCF Per Share | -2.29 |
Margins
Gross margin is 54.90%, with operating and profit margins of -47.00% and -42.34%.
| Gross Margin | 54.90% |
| Operating Margin | -47.00% |
| Pretax Margin | -42.32% |
| Profit Margin | -42.34% |
| EBITDA Margin | -35.13% |
| EBIT Margin | -47.00% |
| FCF Margin | n/a |
Dividends & Yields
Applied BioCode does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.29% |
| Shareholder Yield | -13.29% |
| Earnings Yield | -8.38% |
| FCF Yield | -9.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Applied BioCode has an Altman Z-Score of 3.58 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.58 |
| Piotroski F-Score | 1 |